These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10892222)

  • 21. Fluoxetine: therapeutic and undesirable effects.
    Cookson J; Duffett R
    Hosp Med; 1998 Aug; 59(8):622-6. PubMed ID: 9829055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The mental disorder and obsessive-compulsive spectrum disorders in childhood ].
    Okada T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):992-8. PubMed ID: 22292193
    [No Abstract]   [Full Text] [Related]  

  • 23. Hyperphagia and self-mutilation in Prader-Willi syndrome: psychopharmacological issues.
    Yaryura-Tobias JA; Grunes MS; Bayles ME; Neziroglu F
    Eat Weight Disord; 1998 Dec; 3(4):163-7. PubMed ID: 10728166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preschool children with obsessive-compulsive disorder and fluoxetine treatment.
    Ercan ES; Kandulu R; Akyol Ardic U
    Eur Child Adolesc Psychiatry; 2012 Mar; 21(3):169-72. PubMed ID: 22271063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sertraline-induced enuresis in a prepubertal child resolves after switching to fluoxetine.
    Maalouf FT; Gilbert AR
    J Child Adolesc Psychopharmacol; 2010 Apr; 20(2):161-2. PubMed ID: 20415614
    [No Abstract]   [Full Text] [Related]  

  • 26. An adolescent male with multiple paraphilias successfully treated with fluoxetine.
    Galli VB; Raute NJ; McConville BJ; McElroy SL
    J Child Adolesc Psychopharmacol; 1998; 8(3):195-7. PubMed ID: 9853694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Obsessive-compulsive symptoms in schizophrenia induced by risperidone and responding to fluoxetine.
    Levy E; Margolese HC; Sultan S; Chouinard G
    Can J Psychiatry; 2003 Nov; 48(10):709-10. PubMed ID: 14674056
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The addition of buspirone to SSRI in the treatment of adolescent obsessive-compulsive disorder. A study of six cases.
    Thomsen PH; Mikkelsen HU
    Eur Child Adolesc Psychiatry; 1999 Jun; 8(2):143-8. PubMed ID: 10435463
    [No Abstract]   [Full Text] [Related]  

  • 30. Fluoxetine has no marked effect on tic symptoms in patients with Tourette's syndrome: a double-blind placebo-controlled study.
    Scahill L; Riddle MA; King RA; Hardin MT; Rasmusson A; Makuch RW; Leckman JF
    J Child Adolesc Psychopharmacol; 1997; 7(2):75-85. PubMed ID: 9334893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Symptom remission in OCD after discontinuation of pharmacotherapy with fluoxetine: a case for looking beyond serotonin.
    Zurowski B; Wahl K; Hohagen F; Kordon A
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 May; 31(4):959-60. PubMed ID: 17321024
    [No Abstract]   [Full Text] [Related]  

  • 32. [Self-mutilation of the hand in a girl with total, persistent obstetric brachial plexus palsy--case report].
    Sibiński M; Dorman T; Synder M
    Chir Narzadow Ruchu Ortop Pol; 2008; 73(4):259-60. PubMed ID: 18847017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.
    Besiroglu L; Çetinkaya N; Selvi Y; Atli A
    Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic challenges in comorbid obsessive compulsive disorder with substance use.
    Jain S; Gupta T; Nebhinani N; Singhai K; Suthar N
    Asian J Psychiatr; 2018 Jan; 31():127-128. PubMed ID: 29482123
    [No Abstract]   [Full Text] [Related]  

  • 35. Onychophagia as a spectrum of obsessive-compulsive disorder.
    Pacan P; Grzesiak M; Reich A; Szepietowski JC
    Acta Derm Venereol; 2009; 89(3):278-80. PubMed ID: 19479125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.
    Geller DA; Hoog SL; Heiligenstein JH; Ricardi RK; Tamura R; Kluszynski S; Jacobson JG;
    J Am Acad Child Adolesc Psychiatry; 2001 Jul; 40(7):773-9. PubMed ID: 11437015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder.
    Blázquez A; Mas S; Plana MT; Gassó P; Méndez I; Torra M; Arnaiz JA; Lafuente A; Lázaro L
    J Clin Psychopharmacol; 2014 Jun; 34(3):318-26. PubMed ID: 24743718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary Retention in an Adolescent Patient Caused by Fluoxetine Alone.
    Karadag M; Gokcen C; Bayar H; Aksoy I
    J Child Adolesc Psychopharmacol; 2015 Oct; 25(8):658. PubMed ID: 26485088
    [No Abstract]   [Full Text] [Related]  

  • 39. Obsessive-compulsive spectrum disorders.
    Hollander E; Wong CM
    J Clin Psychiatry; 1995; 56 Suppl 4():3-6; discussion 53-5. PubMed ID: 7713863
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of kleptomania with paroxetine.
    Kraus JE
    J Clin Psychiatry; 1999 Nov; 60(11):793. PubMed ID: 10584771
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.